Cytogenomic investigations of haematological neoplasms, including chromosome banding
analysis, fluorescence in situ hybridisation (FISH) and microarray analyses have become …

Evidence-based recommendations have been established for treatment of chronic myeloid
leukemia (CML) in adults treated with tyrosine kinase inhibitors (TKIs), but the rarity of this …

Five-year survival has increased for many hematologic malignancies in the 21st century.
However, whether this has translated into greater long-term survival is unknown. Here, we …

Regardless of line of therapy, treatment goals in chronic phase chronic myeloid leukemia
(CML) are: avoid progression to accelerated phase or blast crisis CML such that patients …

Ponatinib is associated with cardiovascular adverse events (CAEs), and its frequency in the
real world is limited. In this retrospective study, we examined the survival outcomes and …

Recent genetic analysis using next-generation sequencing (NGS) vastly improved the
understanding of molecular mechanism of hematological malignancies. Many molecular …

Small-molecule inhibitors of tyrosine kinases (TKIs) are the mainstay of treatment for many
malignancies and represent novel treatment options for other diseases such as idiopathic …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by the BCR-ABL1
fusion gene generation as a consequence of the t (9; 22)(q34; q11) rearrangement. The …

CRISPR genome editing approaches theoretically enable researchers to define the function
of each human gene in specific cell types, but challenges remain to efficiently perform …

Patients with chronic myeloid leukemia (CML) often require lifelong therapy with ABL1
tyrosine kinase inhibitors (TKIs) due to a persisting TKI-resistant population of leukemic stem …